
Axiom Biosciences to Seek Hong Kong IPO in 2027, CEO Cites Asia Focus and Funding Needs
The San Diego-based biotech plans to become the first U.S. firm of its kind to pursue a primary listing in Hong Kong, aiming to fund the expansion of its lead drug program into larger adult indications, its CEO said.







